Skip to main content
Premium Trial:

Request an Annual Quote

As Planned, Sequenom Implements Reverse Stock Split in Effort to Regain Nasdaq Compliance

NEW YORK, June 2 (GenomeWeb News) - Sequenom today implemented a planned 1-for-3 reverse stock split in an effort to regain compliance with the Nasdaq exchange.

 

Under the split, each three outstanding shares of common stock are automatically combined and converted into one share. Since fractional shares will not be issued, cash payments will be made for those shares.

 

As GenomeWeb News reported on Wednesday, Sequenom's shareholders approved the split, and to increase the authorized shares of its common stock to 185 million.

 

The reverse split is part of the company's plan to regain compliance with Nasdaq National Market listing requirements. Sequenom last week received a letter saying it was not in compliance. Nasdaq Listing Qualifications Panel will decide whether to grant the company's request to continue being listed.

 

For the next 20 days, the company's Nasdaq ticker symbol will be SQNMD. The ticker symbol will return to the regular SQNM after this period.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.